Agree. Doesn't matter if there was insufficient data included with the IDE OR if the FDA simply ran out of time.
The thing that matters (imo) is that RDGL requested a PreSub filing to discuss matters with the FDA before filing another IDE submission. Most importantly the CEO should know for sure what is going on. But unless someone on the board has an inside source, nobody's opinion on what is going on really matters.
Obviously, everyone can have their own opinion whether it was a lack of data or insufficient time for review, but I believe only the CEO and the FDA know for sure. It should be the CEO's responsibility to inform shareholders what is going on. The FDA also knows, but they aren't talking. lol
my opinions are just that